 Lymphoma, T-Cell, Cutaneous
"Lymphoma, T-Cell, Cutaneous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.
| Descriptor ID |
D016410
|
| MeSH Number(s) |
C04.557.386.480.750.800 C15.604.515.569.480.750.800 C20.683.515.761.480.750.800
|
| Concept/Terms |
Lymphoma, T-Cell, Cutaneous- Lymphoma, T-Cell, Cutaneous
- T-Cell Lymphoma, Cutaneous
- T Cell Lymphoma, Cutaneous
- Cutaneous T-Cell Lymphoma
- Cutaneous T Cell Lymphoma
- Cutaneous T-Cell Lymphomas
- Lymphoma, Cutaneous T-Cell
- Lymphomas, Cutaneous T-Cell
- T-Cell Lymphomas, Cutaneous
- Lymphoma, T Cell, Cutaneous
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, T-Cell, Cutaneous".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Lymphoma [C04.557.386]
- Lymphoma, Non-Hodgkin [C04.557.386.480]
- Lymphoma, T-Cell [C04.557.386.480.750]
- Lymphoma, T-Cell, Cutaneous [C04.557.386.480.750.800]
- Hemic and Lymphatic Diseases [C15]
- Lymphatic Diseases [C15.604]
- Lymphoproliferative Disorders [C15.604.515]
- Lymphoma [C15.604.515.569]
- Lymphoma, Non-Hodgkin [C15.604.515.569.480]
- Lymphoma, T-Cell [C15.604.515.569.480.750]
- Lymphoma, T-Cell, Cutaneous [C15.604.515.569.480.750.800]
- Immune System Diseases [C20]
- Immunoproliferative Disorders [C20.683]
- Lymphoproliferative Disorders [C20.683.515]
- Lymphoma [C20.683.515.761]
- Lymphoma, Non-Hodgkin [C20.683.515.761.480]
- Lymphoma, T-Cell [C20.683.515.761.480.750]
- Lymphoma, T-Cell, Cutaneous [C20.683.515.761.480.750.800]
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, T-Cell, Cutaneous".
This graph shows the total number of publications written about "Lymphoma, T-Cell, Cutaneous" by people in this website by year, and whether "Lymphoma, T-Cell, Cutaneous" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1990 | 1 | 0 | 1 | | 1991 | 3 | 0 | 3 | | 1992 | 0 | 1 | 1 | | 1993 | 2 | 0 | 2 | | 1994 | 3 | 0 | 3 | | 1995 | 1 | 0 | 1 | | 1997 | 1 | 1 | 2 | | 1998 | 2 | 1 | 3 | | 1999 | 1 | 0 | 1 | | 2000 | 3 | 0 | 3 | | 2001 | 5 | 0 | 5 | | 2002 | 2 | 0 | 2 | | 2003 | 5 | 0 | 5 | | 2004 | 3 | 0 | 3 | | 2005 | 3 | 0 | 3 | | 2006 | 2 | 0 | 2 | | 2007 | 3 | 0 | 3 | | 2008 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2012 | 3 | 0 | 3 | | 2016 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Lymphoma, T-Cell, Cutaneous" by people in Profiles.
-
Martinez-Escala ME, Kuzel TM, Kaplan JB, Petrich A, Nardone B, Rosen ST, Guitart J. Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma. JAMA Oncol. 2016 Jun 01; 2(6):790-3.
-
Gammon B, Robson A, Deonizio J, Arkin L, Guitart J. CD8(+) granulomatous cutaneous T-cell lymphoma: a potential association with immunodeficiency. J Am Acad Dermatol. 2014 Sep; 71(3):555-60.
-
Knobler R, Duvic M, Querfeld C, Straus D, Horwitz S, Zain J, Foss F, Kuzel T, Campbell K, Geskin L. Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. Photodermatol Photoimmunol Photomed. 2012 Oct; 28(5):250-7.
-
Thomas TO, Agrawal P, Guitart J, Rosen ST, Rademaker AW, Querfeld C, Hayes JP, Kuzel TM, Mittal BB. Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2013 Mar 01; 85(3):747-53.
-
Bloom T, Kuzel TM, Querfeld C, Guitart J, Rosen ST. Cutaneous T-cell lymphomas: a review of new discoveries and treatments. Curr Treat Options Oncol. 2012 Mar; 13(1):102-21.
-
Querfeld C, Kuzel TM, Kim YH, Porcu P, Duvic M, Musiek A, Rook AH, Mark LA, Pinter-Brown L, Hamid O, Lin B, Bian Y, Boye M, Day JM, Rosen ST. Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Leuk Lymphoma. 2011 Aug; 52(8):1474-80.
-
Kim YH, Girardi M, Duvic M, Kuzel T, Link BK, Pinter-Brown L, Rook AH. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol. 2010 Dec; 63(6):975-83.
-
Gerami P, Rosen S, Kuzel T, Boone SL, Guitart J. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma. Arch Dermatol. 2008 Jun; 144(6):738-46.
-
Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007 Jul 20; 25(21):3109-15.
-
Straus DJ, Duvic M, Kuzel T, Horwitz S, Demierre MF, Myskowski P, Steckel S. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer. 2007 May 01; 109(9):1799-803.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|